NEW YORK (GenomeWeb News) — Molecular diagnostic developer Immunexpress has garnered $6 million in financing led by Switzerland's Debiopharm Group, the companies said today.

Immunexpress, which has locations in Brisbane, Australia, and Seattle, said it will use the funding to advance development of its SeptiCyte technology and to bring one of its late-stage sepsis diagnostic products to market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.